[Current problems in development of new anticancer agents for new molecular targets].
In this report, we present some current problems in the development of new anticancer agents for new molecular targets in the development process: basic research, developing research and clinical trials. Also new proposals are made to solve these problems from our corporate point of view. It will be necessary to work out new rational methods to evaluate toxicity and efficacy considering the mechanisms and pharmacokinetics of drugs to develop new anticancer agents. Changes in clinical evaluation criteria for antitumor agents, from tumor size to survival time an improvement of QOL, will mean increased costs and a longer time for clinical trials. Given these conditions, it will be necessary for companies to co-operate with public research institutes in order to develop new anticancer agents, and to revise the guidelines and systems of clinical trials.